Abstract:
Axitinib is a novel tyrosine kinase inhibitor which is a second-line
option for the treatment of metastatic renal cell carcinoma with progression after previous therapy (1, 2). We present the first reported case
of acute myocardial infarction in a patient receiving axitinib.